SEI Investments’s Alaunos Therapeutics TCRT Stock Holding History

SEI Investments’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-222	Closed	-$57K	–	2671
2022 Q3	$57K	Buy	222 +18	+9%	+$5.23K	﹤0.01%	2618
2022 Q2	$38K	Buy	+204	New	+$19.5K	﹤0.01%	2618
2015 Q4	–	Sell	-342	Closed	-$463K	–	2679
2015 Q3	$463K	Buy	+342	New	+$564K	﹤0.01%	1314
2015 Q2	–	Hold	0	–	–	–	2358

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return

SGCA

Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SEI Investments's TCRT Position: Q4 2022 in Review

SEI Investments sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 222 shares — an estimated $57K sold.

SEI Investments first reported a position in TCRT in Q3 2015 and held it in 3 quarters. The position peaked at $463K in Q3 2015. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

SEI Investments reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
SEI Investments sold 222 Alaunos Therapeutics shares in Q4 2022, an estimated $57K.
SEI Investments first reported a position in Alaunos Therapeutics in Q3 2015 and held it in 3 quarters.
SEI Investments's Alaunos Therapeutics position peaked at $463K in Q3 2015.
122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on SEI Investments's 13F filing for Q4 2022, filed 10 Feb 2023.